Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades.
Saved in:
| Title: | Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades. |
|---|---|
| Authors: | Jamal F; Division of Hematology/Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, United States., Sahvan O; Division of Hematology/Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, United States., Junior PLSU; Division of Hematology/Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, United States., Jones JC; Division of Hematology/Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Jacksonville, FL 32224, United States., Ou FS; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, United States., Bekaii-Saab T; Division of Hematology/Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, United States., Sonbol MB; Division of Hematology/Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, United States. |
| Source: | The oncologist [Oncologist] 2025 Dec 01; Vol. 30 (12). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
